v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue:        
Research and development $ 33,333
Costs and expenses:        
Research and development 2,480,764 3,410,237 5,722,196 7,497,120
General and administrative 2,308,926 2,356,310 5,453,936 4,615,941
Total costs and expenses 4,789,690 5,766,547 11,176,132 12,113,061
Loss from operations (4,789,690) (5,766,547) (11,142,799) (12,113,061)
Sale of New Jersey net operating loss & tax credits 1,328,470 1,073,289
Other income, net (1,415) 156,000 66,904 383,327
Net loss (4,791,105) (5,610,547) (9,747,425) (10,656,445)
Preferred stock series B accumulated dividends (184,899) (177,092) (395,799) (347,792)
Net loss attributable to common shareholders $ (4,976,004) $ (5,787,639) $ (10,143,224) $ (11,004,237)
Net loss available for common shareholders per share - basic and diluted $ (0.02) $ (0.03) $ (0.05) $ (0.06)
Weighted average common shares outstanding - basic and diluted 205,215,259 197,601,500 204,547,251 194,636,326
Other comprehensive (loss)/income, net of tax        
Net unrealized (loss)/gain on securities available-for-sale $ (85,163) $ (41,954) $ (176,929) $ 481,303
Reclassifications to net loss (2,708) (2,719)
Other comprehensive (loss)/income, net of tax (85,163) (44,662) (176,929) 478,584
Comprehensive loss attributable to shareholders $ (4,876,268) $ (5,655,209) $ (9,924,354) $ (10,177,861)

Source